Reviews
Songtao Dong, Xiangnan Guo, Fei Han, Zhonggui He, Yongjun Wang. Emerging role of natural products in cancer immunotherapy[J]. Acta Pharmaceutica Sinica B, 2022, 12(3): 1163-1185

Emerging role of natural products in cancer immunotherapy
Songtao Donga, Xiangnan Guoa, Fei Hanb, Zhonggui Hea, Yongjun Wanga
a. Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China;
b. School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
Abstract:
Cancer immunotherapy has become a new generation of anti-tumor treatment, but its indications still focus on several types of tumors that are sensitive to the immune system. Therefore, effective strategies that can expand its indications and enhance its efficiency become the key element for the further development of cancer immunotherapy. Natural products are reported to have this effect on cancer immunotherapy, including cancer vaccines, immune-check points inhibitors, and adoptive immune-cells therapy. And the mechanism of that is mainly attributed to the remodeling of the tumor-immunosuppressive microenvironment, which is the key factor that assists tumor to avoid the recognition and attack from immune system and cancer immunotherapy. Therefore, this review summarizes and concludes the natural products that reportedly improve cancer immunotherapy and investigates the mechanism. And we found that saponins, polysaccharides, and flavonoids are mainly three categories of natural products, which reflected significant effects combined with cancer immunotherapy through reversing the tumor-immunosuppressive microenvironment. Besides, this review also collected the studies about nano-technology used to improve the disadvantages of natural products. All of these studies showed the great potential of natural products in cancer immunotherapy.
Key words:    Natural products    Cancer immunotherapy    Immunosuppressive microenvironment    Cancer vaccines    Immuno-check points    Adoptive immune-cells transfer immunotherapy   
Received: 2021-04-06     Revised: 2021-06-05
DOI: 10.1016/j.apsb.2021.08.020
Funds: This work was supported by Science and Technology Plan Project of Shenyang (RC200406, China) and the Career Development Program for Young and Middle-aged Teachers in Shenyang Pharmaceutical University (Shenyang, China).
Corresponding author: Fei Han,E-mai:hanfei_spu@163.com;Zhonggui He,E-mai:hezhonggui@syphu.edu.cn;Yongjun Wang,E-mai:wangyongjun@syphu.edu.cn     Email:hanfei_spu@163.com;hezhonggui@syphu.edu.cn;wangyongjun@syphu.edu.cn
Author description:
Service
PDF(KB) Free
Print
0
Authors
Songtao Dong
Xiangnan Guo
Fei Han
Zhonggui He
Yongjun Wang

References:
[1] Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-489
[2] Finck A, Gill SI, June CH. Cancer immunotherapy comes of age and looks for maturity. Nat Commun 2020;11:3325
[3] Hargadon KM, Johnoson CE, Williams CJ. Immune checkpoint blockade therapy for cancer:an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 2018;62:29-39
[4] O'Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D, et al. FDA approval summary:tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res 2019;25:1142-1146
[5] Bouchkouj N, Kasamon YL, de Claro RA, George B, Lin X, Lee S, et al. FDA approval summary:axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin Cancer Res 2019;25:1702-1708
[6] Cheever MA, Hignao CS. PROVENGE (Sipuleucel-T) in prostate cancer:the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011;17:3520-3526
[7] FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Rep 2010;59:630-632
[8] Kirby T. FDA approves new upgraded Gardasil 9. Lancet Oncol 2015;16:e56
[9] FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Rep 2010;59:626-629
[10] York A. Overcoming hurdles in cancer immunotherapy. Nat Rev Microbiol 2021;19:222-223
[11] Ochoa de Olza M, Navarro Rodrigo B, Zimmermann S, Coukos G. Turning up the heat on non-immunoreactive tumours:opportunities for clinical development. Lancet Oncol 2020;21:e419-e430
[12] Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017;168:707-723
[13] Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 2019;18:197-218
[14] O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 2019;16:151-167
[15] Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther 2021;6:72
[16] Garner H, de Visser KE. Immune crosstalk in cancer progression and metastatic spread:a complex conversation. Nat Rev Immunol 2020;20:483-497
[17] Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-296
[18] Hogg SJ, Beavis PA, Dawson MA, Johnstone RW. Targeting the epigenetic regulation of antitumour immunity. Nat Rev Drug Discov 2020;19:776-800
[19] Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression-implications for anticancer therapy. Nat Rev Clin Oncol 2019;16:356-371
[20] Mokbel K, Wazir U, Mokbel K. Chemoprevention of prostate cancer by natural agents:evidence from molecular and epidemiological studies. Anticancer Res 2019;39:5231-5259
[21] Prakash Mishra A, Sharifi-Rad M, Shariati MA, Mabkhot YN, Al-Showiman SS, Rauf A, et al. Bioactive compounds and health benefits of edible Rumex species-a review. Cell Mol Biol 2018;64:27-34
[22] Sun B, Yu S, Zhao D, Guo S, Wang X, Zhao K. Polysaccharides as vaccine adjuvants. Vaccine 2018;36:5226-5234
[23] Bahrami A, Fereidouni M, Pirro M, Bianconi V, Sahebkar A. Modulation of regulatory T cells by natural products in cancer. Cancer Lett 2019;459:72-85
[24] Wang Y, Zhang Q, Chen Y, Liang C-L, Liu H, Qiu F, et al. Antitumor effects of immunity-enhancing traditional Chinese medicine. Biomed Pharmacother 2020;121:109570-70
[25] He J, Yin P, Xu K. Effect and molecular mechanisms of traditional Chinese medicine on tumor targeting tumor-associated macrophages. Drug Des Dev Ther 2020;14:907-919
[26] Sudhakaran M, Sardesai S, Doseff AI. Flavonoids:new frontier for immuno-regulation and breast cancer control. Antioxidants 2019;8:4
[27] Mignani S, Rodrigues J, Tomas H, Zablocka M, Shi X, Caminade AM, et al. Dendrimers in combination with natural products and analogues as anti-cancer agents. Chem Soc Rev 2018;47:514-532
[28] Braicu C, Mehterov N, Vladimirov B, Sarafian V, Nabavi SM, Atanasov AG, et al. Nutrigenomics in cancer:revisiting the effects of natural compounds. Semin Cancer Biol 2017;46:84-106
[29] Efferth T, Saeed MEM, Kadioglu O, Seo EJ, Shirooie S, Mbaveng AT, et al. Collateral sensitivity of natural products in drug-resistant cancer cells. Biotechnol Adv 2020;38:107342
[30] Fontana F, Raimondi M, Di Domizio A, Moretti RM, Montagnani Marelli M, Limonta P. Unraveling the molecular mechanisms and the potential chemopreventive/therapeutic properties of natural compounds in melanoma. Semin Cancer Biol 2019;59:266-282
[31] Ye J, Zhang R, Wu F, Zhai L, Wang K, Xiao M, et al. Non-apoptotic cell death in malignant tumor cells and natural compounds. Cancer Lett 2018;420:210-227
[32] Naysmith BJ, Hume PA, Sperry J, Brimble MA. Pyranonaphthoquinones- isolation, biology and synthesis:an update. Nat Prod Rep 2017;34:25-61
[33] Fontana F, Raimondi M, Marzagalli M, Di Domizio A, Limonta P. The emerging role of paraptosis in tumor cell biology:perspectives for cancer prevention and therapy with natural compounds. Biochim Biophys Acta Rev Cancer 2020;1873:188338
[34] Chhabra G, Singh CK, Ndiaye MA, Fedorowicz S, Molot A, Ahmad N. Prostate cancer chemoprevention by natural agents:clinical evidence and potential implications. Cancer Lett 2018;422:9-18
[35] Garg N, Luzzatto-Knaan T, Melnik AV, Caraballo-Rodriguez AM, Floros DJ, Petras D, et al. Natural products as mediators of disease. Nat Prod Rep 2017;34:194-219
[36] Branca MA. Rekindling cancer vaccines. Nat Biotechnol 2016;34:1019-1024
[37] Ott PA, Hodi FS. Talimogene laherparepvec for the treatment of advanced melanoma. Clin Cancer Res 2016;22:3127-3131
[38] Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577-581
[39] Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition:molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273
[40] Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion:implications for tumor immunotherapy. Cancer Immunol Immunother 2005;54:307-314
[41] Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A 1999;96:11476-11481
[42] van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190:355-366
[43] Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-8377
[44] Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-1736
[45] Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion. Nat Med 2002;8:793-800
[46] Coleman JW. Nitric oxide:a regulator of mast cell activation and mast cell-mediated inflammation. Clin Exp Immunol 2002;129:4-10
[47] Vliagoftis H, Boucher WS, Mak LL, Theoharides TC. Inhibition of mast cell secretion by oxidation products of natural polyamines. Biochem Pharmacol 1992;43:2237-2245
[48] Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 2000;88:2686-2692
[49] Frossi B, De Carli M, Daniel KC, Rivera J, Pucillo C. Oxidative stress stimulates IL-4 and IL-6 production in mast cells by an APE/Ref-1-dependent pathway. Eur J Immunol 2003;33:2168-2177
[50] Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007;217:65-78
[51] Gutzmer R, Diestel C, Mommert S, Kother B, Stark H, Wittmann M, et al. Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J Immunol 2005;174:5224-5232
[52] Worm J, Falkenberg K, Olesen J. Histamine and migraine revisited:mechanisms and possible drug targets. J Headache Pain 2019;20:30
[53] Conti P, Kempuraj D, Kandere K, Di Gioacchino M, Barbacane RC, Castellani ML, et al. IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol Lett 2003;86:123-129
[54] Wasiuk A, de Vries VC, Hartmann K, Roers A, Noelle RJ. Mast cells as regulators of adaptive immunity to tumours. Clin Exp Immunol 2009;155:140-146
[55] Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78
[56] Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression:implications for new anticancer therapies. J Pathol 2002;196:254-265
[57] Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66:5527-5536
[58] Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-612
[59] Khazaie K, von Boehmer H. The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol 2006;16:124-136
[60] Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-964
[61] Finn OJ. The dawn of vaccines for cancer prevention. Nat Rev Immunol 2018;18:183-194
[62] Butterfield LH. Cancer vaccines. BMJ 2015;350:h988
[63] Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013;39:38-48
[64] Melero I, Gustav G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer:an overview of clinical trials. Nat Rev Clin Oncol 2014;11:509-524
[65] Sahin U, Tureci O. Personalized vaccines for cancer immunotherapy. Science 2018;359:1355-1360
[66] Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol 2018;18:168-182
[67] Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013;31:51-72
[68] Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, et al. Consensus guidelines for the detection of immunogenic cell death. OncoImmunology 2014;3:e955691
[69] Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, et al. Classification of current anticancer immunotherapies. Oncotarget 2014;5:12472-12508
[70] Radogna F, Dicato M, Diederich M. Natural modulators of the hallmarks of immunogenic cell death. Biochem Pharmacol 2019;162:55-70
[71] Granato M, Gilardini Montani MS, Filardi M, Faggioni A, Cirone M. Capsaicin triggers immunogenic PEL cell death, stimulates DCs and reverts PEL-induced immune suppression. Oncotarget 2015;6:29543-29554
[72] Basu S, Srivastava P. Immunological role of neuronal receptor vanilloid receptor 1 expressed on dendritic cells. Proc Natl Acad Sci U S A 2005;102:5120-5125
[73] Diaz-Laviada I, Rodriguez-Henche N. The potential antitumor effects of capsaicin. Prog Drug Res 2014;68:181-208
[74] Jung MY, Kang HJ, Moon A. Capsaicin-induced apoptosis in SK-Hep-1 hepatocarcinoma cells involves Bcl-2 downregulation and caspase-3 activation. Cancer Lett 2001;165:139-145
[75] Lee SH, Krisanapun C, Baek SJ. NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3beta, C/EBPbeta and ATF3. Carcinogenesis 2010;31:719-728
[76] Ito K, Nakazato T, Yamato K, Miyakawa Y, Yamada T, Hozumi N, et al. Induction of apoptosis in leukemic cells by homovanillic acid derivative, capsaicin, through oxidative stress:implication of phosphorylation of p53 at Ser-15 residue by reactive oxygen species. Cancer Res 2004;64:1071-1078
[77] Son KJ, Choi KR, Lee SJ, Lee H. Immunogenic cell death induced by ginsenoside Rg3:significance in dendritic cell-based anti-tumor immunotherapy. Immune Netw 2016;16:75-84
[78] Zhang Y, Yang S, Yang Y, Liu T. Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells. Infect Agent Cancer 2019;14:27
[79] Zhang J, Shen L, Li X, Song W, Liu Y, Huang L. Nanoformulated codelivery of Quercetin and Alantolactone promotes an antitumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer. ACS Nano 2019;13:12511-12524
[80] Ward AB, Mir H, Kapur N, Gales DN, Carriere PP, Singh S. Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways. World J Surg Oncol 2018;16:108
[81] Chen HM, Wang PH, Chen SS, Wen CC, Chen YH, Yang WC, et al. Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine. Cancer Immunol Immunother 2012;61:1989-2002
[82] Lin TJ, Lin HT, Chang WT, Mitapalli SP, Hsiao PW, Yin SY, et al. Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components. Mol Cancer 2015;14:174
[83] Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine 2009;27:1787-1796
[84] Livingston PO, Adluri S, Helling F, Yao TJ, Kensil CR, Newman MJ, et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 1994;12:1275-1280
[85] Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 2003;9:5214-5220
[86] Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 2000;85:659-666
[87] Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000;6:1693-1701
[88] Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, et al. A polyvalent vaccine for high-risk prostate patients:"are more antigens better?". Cancer Immunol Immunother 2007;56:1921-1930
[89] Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, et al. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine:clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol Immunother 2005;54:694-702
[90] Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 2007;13:4170-4177
[91] Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res 2004;10:6094-6100
[92] Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-1677
[93] Rhodes J. Evidence for an intercellular covalent reaction essential in antigen-specific T cell activation. J Immunol 1989;143:1482-1489
[94] Marciani DJ, Press JB, Reynolds RC, Pathak AK, Pathak V, Gundy LE, et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 2000;18:3141-3151
[95] Lacaille-Dubois MA, Wagner H. New perspectives for natural triterpene glycosides as potential adjuvants. Phytomedicine 2017
[96] Fernandez-Tejada A, Tan DS, Gin DY. Development of improved vaccine adjuvants based on the saponin natural product QS-21 through chemical synthesis. Acc Chem Res 2016;49:1741-1756
[97] Adams MM, Damani P, Perl NR, Won A, Hong F, Livingston PO, et al. Design and synthesis of potent Quillaja saponin vaccine adjuvants. J Am Chem Soc 2010;132:1939-1945
[98] Castro-Diaz N, Salaun B, Perret R, Sierro S, Romero JF, Fernandez JA, et al. Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines. Vaccine 2012;30:388-397
[99] Zhang XP, Li YD, Luo LL, Liu YQ, Li Y, Guo C, et al. Astragalus saponins and liposome constitute an efficacious adjuvant formulation for cancer vaccines. Cancer Biother Radiopharm 2018;33:25-31
[100] Huang Y, Zou Y, Lin L, Zheng R. Ginsenoside Rg1 activates dendritic cells and acts as a vaccine adjuvant inducing protective cellular responses against lymphomas. DNA Cell Biol 2017;36:1168-1177
[101] Wu L, D'Amico A, Winkel KD, Suter M, Lo D, Shortman K. RelB is essential for the development of myeloid-related CD8alpha- dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells. Immunity 1998;9:839-847
[102] O'Sullivan BJ, Thomas R. CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-kappaB. J Immunol 2002;168:5491-5498
[103] Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res 2009;69:8958-8966
[104] Lu Y, Miao L, Wang Y, Xu Z, Zhao Y, Shen Y, et al. Curcumin micelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model. Mol Ther 2016;24:364-374
[105] Jeong YI, Kim SW, Jung ID, Lee JS, Chang JH, Lee CM, et al. Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cdelta-STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells. J Biol Chem 2009;284:3700-3708
[106] Huang T, Chen Z, Fang L. Curcumin inhibits LPS-induced EMT through downregulation of NF-κB-Snail signaling in breast cancer cells. Oncol Rep 2013;29:117-124
[107] Wei WC, Wang JH, Aravindaram K, Wang SJ, Hsu CC, Li CJ, et al. Polysaccharides from dioscorea (shan yao) and other phytochemicals enhance antitumor effects induced by DNA vaccine against melanoma. J Tradit Complement Med 2014;4:42-48
[108] Chan GC, Chan WK, Sze DM. The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol 2009;2:25
[109] Chang WT, Lai TH, Chyan YJ, Yin SY, Chen YH, Wei WC, et al. Specific medicinal plant polysaccharides effectively enhance the potency of a DC-based vaccine against mouse mammary tumor metastasis. PloS One 2015;10:e0122374
[110] Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27:3135-3142
[111] Lv J, Shao Q, Wang H, Shi H, Wang T, Gao W, et al. Effects and mechanisms of curcumin and basil polysaccharide on the invasion of SKOV3 cells and dendritic cells. Mol Med Rep 2013;8:1580-1586
[112] Pi CC, Chu CL, Lu CY, Zhuang YJ, Wang CL, Yu YH, et al. Polysaccharides from Ganoderma formosanum function as a Th1 adjuvant and stimulate cytotoxic T cell response in vivo. Vaccine 2014;32:401-408
[113] Fitzpatrick JM, Minogue E, Curham L, Tyrrell H, Gavigan P, Hind W, et al. MyD88-dependent and -independent signalling via TLR3 and TLR4 are differentially modulated by Δ9-tetrahydrocannabinol and cannabidiol in human macrophages. J Neuroimmunol 2020;343:577217
[114] Jung TY, Pham TN, Umeyama A, Shoji N, Hashimoto T, Lee JJ, et al. Ursolic acid isolated from Uncaria rhynchophylla activates human dendritic cells via TLR2 and/or TLR4 and induces the production of IFN-gamma by CD4+ naive T cells. Eur J Pharmacol 2010;643:297-303
[115] Lin CC, Pan IH, Li YR, Pan YG, Lin MK, Lu YH, et al. The adjuvant effects of high-molecule-weight polysaccharides purified from Antrodia cinnamomea on dendritic cell function and DNA vaccines. PloS One 2015;10:e0116191
[116] Kim KS, Pham TN, Jin CJ, Umeyama A, Shoji N, Hashimoto T, et al. Uncarinic Acid C isolated from Uncaria rhynchophylla induces differentiation of Th1-promoting dendritic cells through TLR4 signaling. Biomark Insights 2011;6:27-38
[117] Song YC, Huang HC, Chang CY, Lee HJ, Liu CT, Lo HY, et al. A potential herbal adjuvant combined with a peptide-based vaccine acts against HPV-related tumors through enhancing effector and memory T-cell immune responses. Front Immunol 2020;11:62
[118] Yang PM, Du JL, Wang GN, Chia JS, Hsu WB, Pu PC, et al. The Chinese herbal mixture Tien-Hsien liquid augments the anticancer immunity in tumor cell-vaccinated mice. Integr Cancer Ther 2017;16:319-328
[119] Wang L, Zeng W, Wang L, Wang Z, Yin X, Qin Y, et al. Naringenin enhances the antitumor effect of therapeutic vaccines by promoting antigen cross-presentation. J Immunol 2020;204:622-631
[120] Teoh CY, Davies KJ. Potential roles of protein oxidation and the immunoproteasome in MHC class I antigen presentation:the ‘PrOxI’ hypothesis. Arch Biochem Biophys 2004;423:88-96
[121] Amigorena S, Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol 2010;22:109-117
[122] Goswami S, Bose A, Sarkar K, Roy S, Chakraborty T, Sanyal U, et al. Neem leaf glycoprotein matures myeloid derived dendritic cells and optimizes anti-tumor T cell functions. Vaccine 2010;28:1241-1252
[123] Guo L, Shi G, Gao Z, Shen J, Xing R, Qian Z. Response to hepatocarcinoma Hca-F of mice immunized with heat shock protein 70 from elemene combo tumor cell vaccine. Cell Mol Immunol 2006;3:291-295
[124] Ghosh S, Sarkar M, Ghosh T, Guha I, Bhuniya A, Saha A, et al. Neem leaf glycoprotein promotes dual generation of central and effector memory CD8+ T cells against sarcoma antigen vaccine to induce protective anti-tumor immunity. Mol Immunol 2016;71:42-53
[125] Chang JM, Hung LM, Chyan YJ, Cheng CM, Wu RY. Carthamus tinctorius enhances the antitumor activity of dendritic cell vaccines via polarization toward Th1 cytokines and increase of cytotoxic T lymphocytes. Evid Based Complement Alternat Med 2011;2011:274858
[126] Huang CH, Chang CC, Lin CM, Wang ST, Wu MT, Li EI, et al. Promoting effect of Antrodia camphorata as an immunomodulating adjuvant on the antitumor efficacy of HER-2/neu DNA vaccine. Cancer Immunol Immunother 2010;59:1259-1272
[127] Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11:3887-3895
[128] Han L, Yao S, Cao S, Mo G, Li J, Cao Y, et al. Triterpenoid saponins from Anemone flaccida suppress tumor cell proliferation by regulating MAPK, PD1/PDL1, and STAT3 signaling pathways and altering cancer metabolism. OncoTargets Ther 2019;12:10917-10930
[129] Liang J, Li H, Chen J, He L, Du X, Zhou L, et al. Dendrobium officinale polysaccharides alleviate colon tumorigenesis via restoring intestinal barrier function and enhancing anti-tumor immune response. Pharmacol Res 2019;148:104417
[130] Chen Y, Wang Y, Xu L, Zhu W, Xu C, Xu M, et al. Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjogren's syndrome. Int J Rheum Dis 2019;22:200-206
[131] Mazewski C, Kim MS, Gonzalez de Mejia E. Anthocyanins, delphinidin-3-O-glucoside and cyanidin-3-O-glucoside, inhibit immune checkpoints in human colorectal cancer cells in vitro and in silico. Sci Rep 2019;9:11560
[132] Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375-386
[133] Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008;42:145-151
[134] Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell 2019;76:359-370
[135] Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, et al. PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. Clin Cancer Res 2017;23:6054-6061
[136] Ju X, Zhang H, Zhou Z, Wang Q. Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy. Am J Cancer Res 2020;10:1-11
[137] Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, et al. Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med 2018;10
[138] Zhang S, Zhou L, Zhang M, Wang Y, Wang M, Du J, et al. Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin. Front Pharmacol 2019;10:1658
[139] Cuyas E, Perez-Sanchez A, Micol V, Menendez JA, Bosch-Barrera J. STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer. Cell Cycle 2016;15:3413-3418
[140] Ke M, Zhang Z, Xu B, Zhao S, Ding Y, Wu X, et al. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells. Int Immunopharmacol 2019;75:105824
[141] Wang Z, Li MY, Zhang ZH, Zuo HX, Wang JY, Xing Y, et al. Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells. Pharmacol Res 2020;155:104727
[142] Han Z, Liu S, Lin H, Trivett AL, Hannifin S, Yang D, et al. Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses. Cancer Immunol Immunother 2019;68:1073-1085
[143] Xu L, Zhang Y, Tian K, Chen X, Zhang R, Mu X, et al. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects. J Exp Clin Cancer Res 2018;37:261
[144] Coombs MR, Harrison ME, Hoskin DW. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells. Cancer Lett 2016;380:424-433
[145] Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T, et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res 2015;75:5034-5045
[146] Hu M, Yang J, Qu L, Deng X, Duan Z, Fu R, et al. Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-κB pathway in lung adenocarcinoma. Food Funct 2020;11:456-471
[147] Jiang Z, Yang Y, Yang Y, Zhang Y, Yue Z, Pan Z, et al. Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. Biomed Pharmacother 2017;96:378-383
[148] Lu P, Su W, Miao ZH, Niu HR, Liu J, Hua QL. Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer. Chin J Integr Med 2008;14:33-36
[149] Bi S, Huang W, Chen S, Huang C, Li C, Guo Z, et al. Cordyceps militaris polysaccharide converts immunosuppressive macrophages into M1-like phenotype and activates T lymphocytes by inhibiting the PD-L1/PD-1 axis between TAMs and T lymphocytes. Int J Biol Macromol 2020;150:261-280
[150] Hsu PY, Lin YH, Yeh EL, Lo HC, Hsu TH, Su CC. Cordycepin and a preparation from Cordyceps militaris inhibit malignant transformation and proliferation by decreasing EGFR and IL-17RA signaling in a murine oral cancer model. Oncotarget 2017;8:93712-93728
[151] Kongtawelert P, Wudtiwai B, Shwe TH, Pothacharoen P, Phitak T. Inhibitory effect of hesperidin on the expression of programmed death ligand (PD-L1) in breast cancer. Molecules 2020;25
[152] Xu R, Wu J, Zhang X, Zou X, Li C, Wang H, et al. Modified Bu-zhong-yi-qi decoction synergies with 5 fluorouracile to inhibits gastric cancer progress via PD-1/PD- L1-dependent T cell immunization. Pharmacol Res 2020;152:104623
[153] Zhang N, Dou Y, Liu L, Zhang X, Liu X, Zeng Q, et al. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. EBioMedicine 2019;40:151-162
[154] Yao G, Liu C, Huo H, Liu A, Lv B, Zhang C, et al. Ethanol extract of Chaenomeles speciosa Nakai induces apoptosis in cancer cells and suppresses tumor growth in mice. Oncol Lett 2013;6:256-260
[155] Liu W, Fan T, Li M, Zhang G, Guo W, Yang X, et al. Andrographolide potentiates PD-1 blockade immunotherapy by inhibiting COX2-mediated PGE2 release. Int Immunopharmacol 2020;81:106206
[156] Kukhetpitakwong R, Hahnvajanawong C, Homchampa P, Leelavatcharamas V, Satra J, Khunkitti W. Immunological adjuvant activities of saponin extracts from the pods of Acacia concinna. Int Immunopharmacol 2006;6:1729-1735
[157] Dong M, Meng Z, Kuerban K, Qi F, Liu J, Wei Y, et al. Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota. Cell Death Dis 2018;9:1039
[158] Liu S, Han Z, Trivett AL, Lin H, Hannifin S, Yang D, et al. Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma. Cancer Immunol Immunother 2019;68:1059-1071
[159] Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252
[160] Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001;106:259-262
[161] Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-146
[162] Xu H, Hu M, Liu M, An S, Guan K, Wang M, et al. Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model. Biomaterials 2020;235:119769
[163] Hu K, Miao L, Goodwin TJ, Li J, Liu Q, Huang L. Quercetin remodels the tumor microenvironment to improve the permeation, retention, and antitumor effects of nanoparticles. ACS Nano 2017;11:4916-4925
[164] Pei Y, Chen L, Huang Y, Wang J, Feng J, Xu M, et al. Sequential targeting TGF-β signaling and KRAS mutation increases therapeutic efficacy in pancreatic cancer. Small 2019;15:e1900631
[165] Huang Y, Chen Y, Zhou S, Chen L, Wang J, Pei Y, et al. Dual-mechanism based CTLs infiltration enhancement initiated by nano-sapper potentiates immunotherapy against immune-excluded tumors. Nat Commun 2020;11:622
[166] Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359:97-103
[167] Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015;348:62-68
[168] Ma C, Wei Y, Liu Q, Xin Y, Cao G, Wang X, et al. Polysaccharides from Hedyotis diffusa enhance the antitumor activities of cytokine-induced killer cells. Biomed Pharmacother 2019;117:109167
[169] Ju SA, Park SM, Lee YS, Bae JH, Yu R, An WG, et al. Administration of 6-gingerol greatly enhances the number of tumor-infiltrating lymphocytes in murine tumors. Int J Cancer 2012;130:2618-2628
[170] Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, et al. Fucosylation enhances the efficacy of adoptively transferred antigen-specific cytotoxic T lymphocytes. Clin Cancer Res 2019;25:2610-2620
[171] Banerjee S, Ghosh T, Barik S, Das A, Ghosh S, Bhuniya A, et al. Neem leaf glycoprotein prophylaxis transduces immune dependent stop signal for tumor angiogenic switch within tumor microenvironment. PloS One 2014;9:e110040
[172] Chang YF, Chuang HY, Hsu CH, Liu RS, Gambhir SS, Hwang JJ. Immunomodulation of curcumin on adoptive therapy with T cell functional imaging in mice. Cancer Prev Res (Phila) 2012;5:444-452
[173] Xiao Z, Su Z, Han S, Huang J, Lin L, Shuai X. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy. Sci Adv 2020;6:eaay7785
[174] Yu H, Yang Y, Jiang T, Zhang X, Zhao Y, Pang G, et al. Effective radiotherapy in tumor assisted by ganoderma iucidum polysaccharide-conjugated bismuth sulfide nanoparticles through radiosensitization and dendritic cell activation. ACS Appl Mater Interfaces 2019;11:27536-27547
[175] Gu P, Liu Z, Sun Y, Ou N, Hu Y, Liu J, et al. Angelica sinensis polysaccharide encapsulated into PLGA nanoparticles as a vaccine delivery and adjuvant system for ovalbumin to promote immune responses. Int J Pharm 2019;554:72-80
Similar articles:
1.Yuefei Zhu, Xiangrong Yu, Soracha D. Thamphiwatana, Ying Zheng, Zhiqing Pang.Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy[J]. Acta Pharmaceutica Sinica B, 2020,10(11): 2054-2074
Similar articles: